Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
CLA3884 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A49029 | 20953207 | Acta Pharmacol Sin | Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. | 2010 | Details |
| A49038 | 20460903 | Dig Dis | Apoptosis in immune-mediated liver diseases. | 2010 | Details |
| A49053 | 19930687 | BMC Gastroenterol | What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis? | 2009 | Details |
| A49063 | 19594758 | Br J Pharmacol | Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. | 2009 | Details |
| A49068 | 19415399 | J Gastrointest Surg | Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. | 2009 | Details |
| A49088 | 18410556 | Aliment Pharmacol Ther | Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. | 2008 | Details |
| A49097 | 17919273 | Aliment Pharmacol Ther | Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. | 2007 | Details |
| A49104 | 17587244 | Pathol Int | Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes. | 2007 | Details |
| A49107 | 17406752 | Arq Gastroenterol | [Steatosis and non-alcoholic steatohepatitis in patients with chronic hepatitis due to hepatitis C virus infection]. | 2007 | Details |
| A49127 | 16555625 | Trans Am Clin Climatol Assoc | Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings. | 2005 | Details |
| A49139 | 16477590 | J Pathol | Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related? | 2006 | Details |
| A49159 | 15841433 | Genet Mol Res | Hereditary hemochromatosis in a Brazilian university hospital in São Paulo State (1990-2000). | 2005 | Details |
| A49192 | 14585066 | Expert Opin Drug Saf | Hepatotoxicity of thiazolidinediones. | 2003 | Details |
| A49203 | 35830037 | Arq Gastroenterol | OBSTRUCTIVE SLEEP APNEA SYNDROME RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH OBESITY AND PRESENCE OF NASH. | 2022 | Details |
| A49208 | 35822119 | JGH Open | Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. | 2022 | Details |
| A49214 | 35817677 | J Diabetes Complications | Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity. | 2022 | Details |
| A49215 | 35820779 | Gut | Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis. | 2022 | Details |
| A49233 | 35814507 | J Clin Exp Hepatol | Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study. | 2022 | Details |
| A49235 | 35812989 | EClinicalMedicine | Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis. | 2022 | Details |
| A49245 | 35811658 | Dis Markers | Pharmacological Mechanism of Ganlu Powder in the Treatment of NASH Based on Network Pharmacology and Molecular Docking. | 2022 | Details |
| A49255 | 35808891 | J Clin Lab Anal | Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States. | 2022 | Details |
| A49262 | 35806934 | J Clin Med | The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. | 2022 | Details |
| A49265 | 35806447 | Int J Mol Sci | New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49274 | 35804799 | Foods | Consumption of Grapes Modulates Gene Expression, Reduces Non-Alcoholic Fatty Liver Disease, and Extends Longevity in Female C57BL/6J Mice Provided with a High-Fat Western-Pattern Diet. | 2022 | Details |
| A49281 | 35802264 | Clin Exp Med | MiR-1290: a potential therapeutic target for regenerative medicine or diagnosis and treatment of non-malignant diseases. | 2022 | Details |
| A49295 | 35796566 | Obes Rev | Pathophysiology roles for adenosine 2A receptor in obesity and related diseases. | 2022 | Details |
| A49299 | 35795562 | Front Pharmacol | Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction. | 2022 | Details |
| A49311 | 35791792 | Rev Esp Enferm Dig | Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort. | 2022 | Details |
| A49322 | 35789194 | Liver Int | Impact of Liver Fibrosis Score on the incidence of stroke: A cohort study. | 2022 | Details |
| A49337 | 35784557 | Front Endocrinol (Lausanne) | Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis. | 2022 | Details |
| A49351 | 35780909 | Metabolism | Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). | 2022 | Details |
| A49355 | 35779864 | Drug Metab Dispos | Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A49362 | 35778474 | Sci Rep | Multimodal NASH prognosis using 3D imaging flow cytometry and artificial intelligence to characterize liver cells. | 2022 | Details |
| A49368 | 35774609 | Front Pharmacol | Exploring Ganweikang Tablet as a Candidate Drug for NAFLD Through Network Pharmacology Analysis and Experimental Validation. | 2022 | Details |
| A49374 | 35770155 | Front Microbiol | Gut Microbial Profile in Asymptomatic Gallstones. | 2022 | Details |
| A49379 | 35769031 | Clin Transl Sci | The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease. | 2022 | Details |
| A49380 | 35768944 | Clin Obes | The prevalence of comorbidities in Danish patients with obesity - A Danish register-based study based on data from 2002 to 2018. | 2022 | Details |
| A49394 | 35765391 | Cureus | The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A49403 | 35762159 | Curr Opin Clin Nutr Metab Care | Intrahepatic triglyceride content: influence of metabolic and genetics drivers. | 2022 | Details |
| A49406 | 35760549 | BMJ Open | Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. | 2022 | Details |
| A49407 | 35760372 | Diabetes Metab | Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. | 2022 | Details |
| A49426 | 35753609 | J Ethnopharmacol | Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis. | 2022 | Details |
| A49434 | 35749236 | J Nat Prod | Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway. | 2022 | Details |
| A49454 | 35745172 | Nutrients | A Cross-Sectional Pilot Study on Food Intake Patterns Identified from Very Short FFQ and Metabolic Factors Including Liver Function in Healthy Japanese Adults. | 2022 | Details |
| A49478 | 35740464 | Biomedicines | The Emerging Role of Branched-Chain Amino Acids in Liver Diseases. | 2022 | Details |
| A49488 | 35739957 | Antioxidants (Basel) | Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. | 2022 | Details |
| A49498 | 35736186 | Mar Drugs | Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A49518 | 35728958 | Cas Lek Cesk | Diagnostic methods of fatty liver diseases. | 2022 | Details |
| A49529 | 35725419 | BMC Pregnancy Childbirth | The association between chronic liver diseases and preeclampsia. | 2022 | Details |
| A49540 | 35721171 | Front Pharmacol | Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification. | 2022 | Details |
| A49541 | 35721143 | Front Pharmacol | Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice. | 2022 | Details |
| A49544 | 35720181 | Oxid Med Cell Longev | Chrysin Attenuates Fructose-Induced Nonalcoholic Fatty Liver in Rats via Antioxidant and Anti-Inflammatory Effects: The Role of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis. | 2022 | Details |
| A49545 | 35720167 | World J Gastrointest Pathophysiol | Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities. | 2022 | Details |
| A49549 | 35718233 | Life Sci | Physical exercise and the functions of microRNAs. | 2022 | Details |
| A49555 | 35715982 | Liver Transpl | Waitlist and Post-Transplantation Outcomes of Lean Individuals with Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A49569 | 35710106 | Br J Nutr | Long non-coding RNA-EN_181 potentially contributes to the protective effects of N-acetylcysteine against non-alcoholic fatty liver disease in mice. | 2022 | Details |
| A49570 | 35710086 | Ann Hepatol | African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. | 2022 | Details |
| A49584 | 35705686 | Acta Pharmacol Sin | Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease. | 2022 | Details |
| A49670 | 35675435 | Sci Transl Med | Risk assessment with gut microbiome and metabolite markers in NAFLD development. | 2022 | Details |
| A49681 | 35672527 | Heart Vessels | Prognostic value of pericoronary adipose tissue attenuation in patients with non-alcoholic fatty liver disease with suspected coronary artery disease. | 2022 | Details |
| A49682 | 35672379 | Lab Invest | Deletion of Smurf1 attenuates liver steatosis via stabilization of p53. | 2022 | Details |
| A49700 | 35665122 | World J Clin Cases | COVID-19 and liver diseases, what we know so far. | 2022 | Details |
| A49701 | 35665109 | World J Clin Cases | Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease. | 2022 | Details |
| A49709 | 35662921 | Front Nutr | High Protein Diets Improve Liver Fat and Insulin Sensitivity by Prandial but Not Fasting Glucagon Secretion in Type 2 Diabetes. | 2022 | Details |
| A49718 | 35659603 | Clin Res Hepatol Gastroenterol | Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A49753 | 35647047 | Front Cardiovasc Med | Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort. | 2022 | Details |
| A49754 | 35646540 | Acta Pharm Sin B | Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. | 2021 | Details |
| A49773 | 35642526 | Expert Opin Emerg Drugs | Emerging drugs for the treatment of hepatocellular carcinoma. | 2022 | Details |
| A49775 | 35642168 | Sichuan Da Xue Xue Bao Yi Xue Ban | [Research Progress in High-Sugar Diet and Inflammatory Diseases]. | 2022 | Details |
| A49779 | 35639744 | PLoS One | A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. | 2022 | Details |
| A49783 | 35639037 | J Physiol Pharmacol | Are insulin resistance and non-alcoholic fatty liver disease associated with Peyronie's disease? A pilot study. | 2022 | Details |
| A49789 | 35636583 | Metabolism | Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study. | 2022 | Details |
| A49810 | 35630058 | Medicina (Kaunas) | Chronic Inflammation-A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. | 2022 | Details |
| A49821 | 35628443 | Int J Mol Sci | Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. | 2022 | Details |
| A49824 | 35627987 | Healthcare (Basel) | Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A49837 | 35624786 | Antioxidants (Basel) | The Role and Mechanisms of Selenium Supplementation on Fatty Liver-Associated Disorder. | 2022 | Details |
| A49843 | 35624084 | J Gastroenterol Hepatol | Gut microbial community differentially characterizes patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A49846 | 35623174 | Biomed Pharmacother | Corydalis saxicola Bunting Total Alkaloids ameliorate diet-induced non-alcoholic steatohepatitis by regulating hepatic PI3K/Akt and TLR4/NF-κB pathways in mice. | 2022 | Details |
| A49861 | 35616069 | Food Funct | Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis. | 2022 | Details |
| A49870 | 35613974 | Ultrasound Med Biol | Intra-individual Comparisons of the Ultrasound-Guided Attenuation Parameter and the Magnetic Resonance Imaging-Based Proton Density Fat Fraction Using Bias and Precision Statistics. | 2022 | Details |
| A49871 | 35613944 | J Gastroenterol Hepatol | Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation. | 2022 | Details |
| A49873 | 35612975 | Nephrol Dial Transplant | Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than does fatty liver or nonalcoholic fatty liver disease. | 2022 | Details |
| A49874 | 35612851 | JAMA Dermatol | Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults. | 2022 | Details |
| A49876 | 35611668 | Gut Liver | Impact of Evolutionary Changes in Nonalcoholic Fatty Liver Disease on Lung Function Decline. | 2022 | Details |
| A49879 | 35611223 | JMA J | Positive Pattern Recognition System Using Alanine Aminotransferase, Type IV Collagen 7s, and E Value (Liver Stiffness) for the Diagnosis of Nonalcoholic Steatohepatitis Based on Natural History. | 2022 | Details |
| A49890 | 35605893 | Clin Res Hepatol Gastroenterol | The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound. | 2022 | Details |
| A49892 | 35605744 | J Hepatol | Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. | 2022 | Details |
| A49910 | 35599922 | Ann Gastroenterol | Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. | 2022 | Details |
| A49913 | 35598686 | Gene | Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A49926 | 35592291 | Food Sci Nutr | Sodium in relation with nonalcoholic fatty liver disease: A systematic review and meta-analysis of observational studies. | 2022 | Details |
| A49937 | 35588737 | Horm Metab Res | Insulin-Like Growth Factor-I Might be a Predictor for Severe Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients. | 2022 | Details |
| A49955 | 35583480 | J Agric Food Chem | Spermidine Ameliorates Nonalcoholic Steatohepatitis through Thyroid Hormone-Responsive Protein Signaling and the Gut Microbiota-Mediated Metabolism of Bile Acids. | 2022 | Details |
| A49960 | 35582287 | World J Hepatol | Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study. | 2022 | Details |
| A49963 | 35581577 | BMC Med Imaging | Comparison of reader agreement, correlation with liver biopsy, and time-burden sampling strategies for liver proton density fat fraction measured using magnetic resonance imaging in patients with obesity: a secondary cross-sectional study. | 2022 | Details |
| A49971 | 35578028 | Inflamm Res | Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet. | 2022 | Details |
| A49976 | 35576742 | Phytomedicine | Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy. | 2022 | Details |
| A49980 | 35574336 | Front Oncol | A New SteatoScore in the Evaluation of Non-Alcoholic Liver Disease in Oncologic Patients. | 2022 | Details |
| A50002 | 35566571 | J Clin Med | Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. | 2022 | Details |
| A50026 | 35559268 | Front Pharmacol | Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease. | 2022 | Details |
| A50033 | 35556175 | Clin Oral Investig | Periodontal disease could be a potential risk factor for non-alcoholic fatty liver disease: An 11-year retrospective follow-up study. | 2022 | Details |